Essential hypertension is a complex clinical condition, characterized by sustained elevation of systolic and/or diastolic blood pressure (BP) levels and an increased risk of developing major cardiovascular (CV) outcomes, mostly including coronary artery disease, stroke, and death. Several studies have also reported that high BP levels are significantly related to AC higher risk of new- onset congestive heart failure than normotension and that hypertensive disease (i.e., left ventricular diastolic dysfunction with or without left ventricular remodeling or hypertrophy) may be responsible of the progression from hypertension toward left ventricular systolic dys- function and clinically evident heart failure, indepen- dently of the presence of concomitant conditions and co- morbidities

Antihypertensive Efficacy of lcz696 in Hypertension / Tocci, Giuliano. - In: CARDIOLOGY. - ISSN 0008-6312. - 145:9(2020), pp. 1-2. [10.1159/000508345]

Antihypertensive Efficacy of lcz696 in Hypertension

Tocci, Giuliano
Writing – Original Draft Preparation
2020

Abstract

Essential hypertension is a complex clinical condition, characterized by sustained elevation of systolic and/or diastolic blood pressure (BP) levels and an increased risk of developing major cardiovascular (CV) outcomes, mostly including coronary artery disease, stroke, and death. Several studies have also reported that high BP levels are significantly related to AC higher risk of new- onset congestive heart failure than normotension and that hypertensive disease (i.e., left ventricular diastolic dysfunction with or without left ventricular remodeling or hypertrophy) may be responsible of the progression from hypertension toward left ventricular systolic dys- function and clinically evident heart failure, indepen- dently of the presence of concomitant conditions and co- morbidities
2020
hypertension; heart failure; antihypertensive therapy; lcz696
01 Pubblicazione su rivista::01a Articolo in rivista
Antihypertensive Efficacy of lcz696 in Hypertension / Tocci, Giuliano. - In: CARDIOLOGY. - ISSN 0008-6312. - 145:9(2020), pp. 1-2. [10.1159/000508345]
File allegati a questo prodotto
File Dimensione Formato  
Tocci_Antihypertensive_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 62.65 kB
Formato Adobe PDF
62.65 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1427523
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact